Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
- Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap
- WHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agencies
- Novartis making treatment available on largely not-for-profit basis in areas where malaria is endemic
